Drug Database · Clinicians

Carbidopa + Levodopa

Also known as: co-careldopa (British name)

Brands (15) LC-Dopa, Lavida, Levocarbdin…Show all

US brand (reference label): SINEMET; not a Philippine-registered brand.

Aromatic Amino Acid; Aromatic Amino Acid Decarboxylation Inhibitor (DOPA Decarboxylase Inhibitors) US FDA class
Antiparkinson (dopaminergics); Antiparkinsonism (dopaminergic); and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug25 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 9b17b028-964a-473c-823d-81423535bd66, version date August 1, 2026 (SINEMET · Organon LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE SINEMET is indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE SINEMET is indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on SINEMET.

This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. Carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa.

Contraindications

CONTRAINDICATIONS Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with SINEMET. These inhibitors must be discontinued at least two weeks prior to initiating therapy with SINEMET. SINEMET may be administered concomitantly with the manufacturer's recommended dose of an MAO inhibitor with selectivity for MAO type B (e.g., selegiline HCl) (see PRECAUTIONS, Drug Interactions). SINEMET is contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION SINEMET 25-250 tablets are no longer marketed. For dosing with 25-250 strength, use another carbidopa and levodopa product. The optimum daily dosage of SINEMET must be determined by careful titration in each patient. SINEMET tablets are available in a 1:4 ratio of carbidopa to levodopa (SINEMET 25-100) as well as 1:10 ratio (carbidopa and levodopa 25-250 and SINEMET 10-100).

Tablets of the two ratios may be given separately or combined as needed to provide the optimum dosage. Studies show that peripheral dopa decarboxylase is saturated by carbidopa at approximately 70 to 100 mg a day. Patients receiving less than this amount of carbidopa are more likely to experience nausea and vomiting. Management of Vitamin B 6 Levels Evaluate vitamin B 6 levels prior to initiating carbidopa/levodopa therapies, including SINEMET, periodically during treatment, and as clinically indicated (see WARNINGS, Vitamin B6 Deficiency and Seizures).

If vitamin B 6 levels are low, supplement to sufficient levels per standard of care. Patients may initiate and continue treatment with SINEMET while supplementing vitamin B 6. Usual Initial Dosage Dosage is best initiated with one tablet of SINEMET 25-100 three times a day. This dosage schedule provides 75 mg of carbidopa per day.

Dosage may be increased by one tablet every day or every other day, as necessary, until a dosage of eight tablets of SINEMET 25-100 a day is reached. If SINEMET 10-100 is used, dosage may be initiated with one tablet three or four times a day. However, this will not provide an adequate amount of carbidopa for many patients.

Dosage may be increased by one tablet every day or every other day until a total of eight tablets (2 tablets q.i.d.) is reached. How to Transfer Patients from Levodopa Levodopa must be discontinued at least twelve hours before starting SINEMET. A daily dosage of SINEMET should be chosen that will provide approximately 25% of the previous levodopa dosage.

Patients who are taking less than 1500 mg of levodopa a day should be started on one tablet of SINEMET 25-100 three or four times a day. The suggested starting dosage for most patients taking more than 1500 mg of levodopa is one tablet of carbidopa and levodopa 25-250 three or four times a day. Maintenance Therapy should be individualized and adjusted according to the desired therapeutic response.

At least 70 to 100 mg of carbidopa per day should be provided. When a greater proportion of carbidopa is required, one tablet of SINEMET 25-100 may be substituted for each tablet of SINEMET 10-100. When more levodopa is required, carbidopa and levodopa 25-250 should be substituted for SINEMET 25-100 or SINEMET 10-100. If necessary, the dosage of carbidopa and levodopa 25-250 may be increased by one-half or one tablet every day or every other day to a maximum of eight tablets a day.

Experience with total daily dosages of carbidopa greater than 200 mg is limited. Because both therapeutic and adverse responses occur more rapidly with SINEMET than with levodopa alone, patients should be monitored closely during the dose adjustment period. Specifically, involuntary movements will occur more rapidly with SINEMET than with levodopa.

The occurrence of involuntary movements may require dosage reduction. Blepharospasm may be a useful early sign of excess dosage in some patients. Addition of Other Antiparkinsonian Medications Standard drugs for Parkinson's disease, other than levodopa without a decarboxylase inhibitor, may be used concomitantly while SINEMET is being administered, although dosage adjustments may be required.

Interruption of Therapy Sporadic cases of hyperpyrexia and confusion have been associated with dose reductions and withdrawal of SINEMET. Patients should be observed carefully if abrupt reduction or discontinuation of SINEMET is required, especially if the patient is receiving neuroleptics. (See WARNINGS.) If general anesthesia is required, SINEMET may be continued as long as the patient is permitted to take fluids and medication by mouth.

If therapy is interrupted temporarily, the patient should be observed for symptoms resembling NMS, and the usual daily dosage may be administered as soon as the patient is able to take oral medication.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness in pediatric patients have not been established. Use of the drug in patients below the age of 18 is not recommended.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use In the clinical efficacy trials for SINEMET, almost half of the patients were older than 65, but few were older than 75. No overall meaningful differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals to adverse drug reactions such as hallucinations cannot be ruled out. There is no specific dosing recommendation based upon clinical pharmacology data as SINEMET is titrated as tolerated for clinical effect.

Dosage forms

Philippines

  • Tablet: 100 mg/25 mg, 250 mg/25 mg
  • Controlled-release tablet: 200 mg/50 mg

Registered products in the Philippines

25 products registered with the Food and Drug Administration (FDA) Philippines list Carbidopa + Levodopa as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products25
Philippine FDA-registered products for Carbidopa + Levodopa
Package insert
LavidaLevodopa + Carbidopa
100 mg / 25 mg TabletAluminum Flex Foil x 10's (Box of 30's)
Rx
UNILAB, INC.Philippines
—
DR-XY37524
Mar 6, 2037
LavidaLevodopa + Carbidopa
250 mg / 25 mg TabletAluminum Flex Foil x 10's (Box of 30's)
Rx
UNILAB, INC.Philippines
—
DR-XY37438
Feb 20, 2037
LC-DopaLevodopa + Carbidopa (as monohydrate)
100 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Baroque Pharmaceuticals Pvt. Ltd.India
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-15563
Aug 14, 2029
LC-DopaLevodopa + Carbidopa
100 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc
DRP-16981
Sep 3, 2030
LC-DopaLevodopa +Carbidopa
250 mg/25 mg TabletAlu-Alu blister pack x 10's (Box of 30's)
Rx
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-16089
Oct 30, 2029
LC-DopaLevodopa + Carbidopa
250 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's
Rx
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc
DRP-16982
Sep 3, 2030
LevocarbdinLevodopa + Carbidopa
100 mg/25 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Medochemie Ltd. (Central Factory)Cyprus
Medchoice CNS Pharma CorporationImporter: Ambicare Pharmaceuticals Inc.
DRP-7709-01
Feb 26, 2028
LevocarbdinLevodopa + Carbidopa
250 mg/25 mg TabletPVC/Alu Blister Pack x 10's (Box of 100's)
Rx
Medochemie Ltd. (Central Factory)Cyprus
Medchoice CNS Pharma CorporationImporter: Ambicare Pharmaceuticals Inc.
DRP-7708-01
Feb 26, 2028
Medolev 125Levodopa + Carbidopa
100 mg/25 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Medochemie Ltd. (Central Factory)Cyprus
Multicare Pharmaceuticals Phils. Inc.Importer: Ambicare Pharmaceuticals Inc.
DRP-7709
Feb 26, 2028
Medolev 275Levodopa + Carbidopa
250 mg/25 mg TabletPVC/Alu Blister Pack x 10's (Box of 100's)
Rx
Medochemie Ltd. (Central Factory)Cyprus
Multicare Pharmaceuticals Phils. Inc.Importer: Ambicare Pharmaceuticals Inc.
DRP-7708
Feb 26, 2028
NoneLevodopa + Carbidopa
200 mg/50 mg Controlled Release TabletAluminum Foil Strip x 10’s (Box of 50’s)
Rx
Sun Pharma Laboratories LimitedIndia
Ritemed Phils., Inc.Importer: Sun Pharma Philippines, Inc.
DRP-8670-02
Aug 11, 2027
NoneLevodopa + Carbidopa
250 mg/25 mg TabletAluminum Foil Strip x 10’s (Box of 50’s)
Rx
Sun Pharma Laboratories Ltd.India
Ritemed Phils., Inc.Importer: Sun Pharma Philippines, Inc.
DRP-8665-01
Aug 11, 2027
PardopaLevodopa + Carbidopa
250 mg/25 mg TabletAlu/Alu Foil Strip x 10's (Box of 60's)
Rx
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DR-XY40429
Dec 19, 2031
Parkimet 125Levodopa + Carbidopa
100 mg/ 25 mg TabletFoil Strip x 10's (Box of 50's)
Rx
Sun Pharma Philippines, Inc.India
Sun Pharma Philippines, Inc.
DRP-9334
Jul 28, 2027
Roligvo 250Levodopa + Carbidopa
250 mg / 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s)
Rx
Exemed PharmaceuticalsIndia
Emcure Pharma Philippines Inc.Importer: AMB HK Enterprises Inc.
DRP-16982-01
Sep 3, 2030
SinedinLevodopa + Carbidopa (as monohydrate)
100 mg/25 mg TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 100's)
Rx
Sydenham Laboratories, Inc.Philippines
Trader: Medchoice CNS Pharma Corporation
DR-XY41871
Mar 26, 2028
SinedinLevodopa + Carbidopa
250 mg / 25 mg TabletAlu/PVC White Opaque Blister Pack x 10's (Box of 100's)
Rx
Sydenham Laboratories, Inc.Philippines
Trader: MedChoice CNS Pharma Corporation
DR-XY41327
Nov 20, 2027
TidometLevodopa + Carbidopa
250 mg/25 mg TabletAluminum Foil Strip x 10's (Box of 100's)
Rx
TORRENT PHARMACEUTICALS LTD.India
TORRENT PHARMA PHILIPPINES, INC.
DRP-2770
May 16, 2028
Tidomet CRLevodopa + Carbidopa
200 mg/50 mg Controlled Release TabletAluminum Foil Strip x 10's (Box of 30's)
Rx
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DRP-2769
Apr 24, 2028
TwindopaLevodopa + Carbidopa (as monohydrate)
250mg / 25mg TabletAlu/Alu Blister Pack x 10's (Box of 100's); Alu-Alu Blister Pack x 2's (Physician Sample)
Rx
Kusum Healthcare Pvt. Ltd.India
Kusum Healthcare Private Limited Branch Office
DR-XY47373
Sep 9, 2031
VexdopaLevodopa + Carbidopa (as monohydrate)
250 mg/25 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
Rx
West Coast Pharmaceutical Works Ltd.India
VE Pharma, Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DR-XY46969
Aug 19, 2030
VexdopaLevodopa + Carbidopa
250 mg/25 mg TabletPVC/Alu Blister Pack x 10's (Box of 100's)
Rx
Medochemie Ltd. (Central Factory)Cyprus
VE Pharma Inc.Importer: Ambicare Pharmaceuticals Inc.
DRP-7708-02
Feb 26, 2028
Vexdopa 125Levodopa + Carbidopa
100 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
West Coast Pharmaceutical Works Ltd.India
Ve Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DR-XY49495
Sep 5, 2030
Vexdopa 250 CRLevodopa + Carbidopa
200 mg/50 mg Controlled-Release TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
West Coast Pharmaceutical Works Ltd.India
Ve Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DR-XY49440
Jul 11, 2030
(no brand name)Levodopa + Carbidopa
250 mg / 25 mg TabletAluminum foil strip x 10 tablets (box of 30 tablets)
Rx
Micro Labs LimitedIndia
United Laboratories, Inc.Trader: Ritemed Phils., Inc.
DR-XY47964
Apr 25, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS When SINEMET is to be given to patients who are being treated with levodopa, levodopa must be discontinued at least twelve hours before therapy with SINEMET is started. In order to reduce adverse reactions, it is necessary to individualize therapy. See DOSAGE AND ADMINISTRATION section before initiating therapy.

The addition of carbidopa with levodopa in the form of SINEMET reduces the peripheral effects (nausea, vomiting) due to decarboxylation of levodopa; however, carbidopa does not decrease the adverse reactions due to the central effects of levodopa. Because carbidopa permits more levodopa to reach the brain and more dopamine to be formed, certain adverse central nervous system (CNS) effects, e.g., dyskinesias (involuntary movements), may occur at lower dosages and sooner with SINEMET than with levodopa alone.

All patients should be observed carefully for the development of depression with concomitant suicidal tendencies. SINEMET should be administered cautiously to patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease. As with levodopa, care should be exercised in administering SINEMET to patients with a history of myocardial infarction who have residual atrial, nodal, or ventricular arrhythmias.

In such patients, cardiac function should be monitored with particular care during the period of initial dosage adjustment, in a facility with provisions for intensive cardiac care. As with levodopa, treatment with SINEMET may increase the possibility of upper gastrointestinal hemorrhage in patients with a history of peptic ulcer.

Vitamin B 6 Deficiency and Seizures Treatment with SINEMET may contribute to reduced vitamin B 6 levels. Higher doses of carbidopa/levodopa may increase the risk of vitamin B 6 deficiency. Seizures associated with vitamin B 6 deficiency have been reported in the postmarketing setting in patients taking SINEMET. In these reported cases, seizures were refractory to traditional anti-seizure medications and only resolved after vitamin B 6 administration.

Other symptoms of vitamin B 6 deficiency may occur, including depression, confusion, cheilosis, glossitis, dermatitis, anemia, and/or neuropathy. Evaluate vitamin B 6 levels prior to initiation of SINEMET and periodically while on treatment or if symptoms associated with vitamin B 6 deficiency are identified. Supplement with vitamin B 6 as necessary.

Falling Asleep During Activities of Daily Living and Somnolence Patients taking SINEMET alone or with other dopaminergic drugs have reported suddenly falling asleep without prior warning of sleepiness while engaged in activities of daily living (includes operation of motor vehicles). Road traffic accidents attributed to sudden sleep onset have been reported.

Although many patients reported somnolence while on dopaminergic medications, there have been reports of road traffic accidents attributed to sudden onset of sleep in which the patient did not perceive any warning signs, such as excessive drowsiness, and believed that they were alert immediately prior to the event. Sudden onset of sleep has been reported to occur as long as one year after the initiation of treatment.

Falling asleep while engaged in activities of daily living usually occurs in patients experiencing pre-existing somnolence, although some patients may not give such a history. For this reason, prescribers should reassess patients for drowsiness or sleepiness especially since some of the events occur well after the start of treatment.

Prescribers should be aware that patients may not acknowledge drowsiness or sleepiness until directly questioned about drowsiness or sleepiness during specific activities. Patients should be advised to exercise caution while driving or operating machines during treatment with SINEMET. Patients who have already experienced somnolence or an episode of sudden sleep onset should not participate in these activities during treatment with SINEMET.

Before initiating treatment with SINEMET, advise patients about the potential to develop drowsiness and ask specifically about factors that may increase the risk for somnolence with SINEMET such as the use of concomitant sedating medications and the presence of sleep disorders. Consider discontinuing SINEMET in patients who report significant daytime sleepiness or episodes of falling asleep during activities that require active participation (e.g., conversations, eating, etc.).

If treatment with SINEMET continues, patients should be advised not to drive and to avoid other potentially dangerous activities that might result in harm if the patients become somnolent. There is insufficient information to establish that dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living.

Hyperpyrexia and Confusion Sporadic cases of a symptom complex resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reductions or withdrawal of certain antiparkinsonian agents such as levodopa, carbidopa and levodopa, or carbidopa and levodopa extended release. Therefore, patients should be observed carefully when the dosage of levodopa is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics.

NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia. Neurological findings, including muscle rigidity, involuntary movements, altered consciousness, mental status changes; other disturbances, such as autonomic dysfunction, tachycardia, tachypnea, sweating, hyper- or hypotension; laboratory findings, such as creatine phosphokinase elevation, leukocytosis, myoglobinuria, and increased serum myoglobin have been reported.

The early diagnosis of this condition is important for the appropriate management of these patients. Considering NMS as a possible diagnosis and ruling out other acute illnesses (e.g., pneumonia, systemic infection, etc.) is essential. This may be especially complex if the clinical presentation includes both serious medical illness and untreated or inadequately treated extrapyramidal signs and symptoms (EPS).

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. The management of NMS should include: 1) intensive symptomatic treatment and medical monitoring and 2) treatment of any concomitant serious medical problems for which specific treatments are available.

Dopamine agonists, such as bromocriptine, and muscle relaxants, such as dantrolene, are often used in the treatment of NMS; however, their effectiveness has not been demonstrated in controlled studies.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Caution should be exercised when the following drugs are administered concomitantly with SINEMET. Symptomatic postural hypotension occurred when SINEMET was added to the treatment of a patient receiving antihypertensive drugs. Therefore, when therapy with SINEMET is started, dosage adjustment of the antihypertensive drug may be required.

For patients receiving MAO inhibitors (Type A or B), see CONTRAINDICATIONS. Concomitant therapy with selegiline and carbidopa and levodopa may be associated with severe orthostatic hypotension not attributable to carbidopa and levodopa alone (see CONTRAINDICATIONS). There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and SINEMET.

Dopamine D 2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa. In addition, the beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by phenytoin and papaverine. Patients taking these drugs with SINEMET should be carefully observed for loss of therapeutic response.

Use of SINEMET with dopamine-depleting agents (e.g., reserpine and tetrabenazine) or other drugs known to deplete monoamine stores is not recommended. SINEMET and iron salts or multivitamins containing iron salts should be coadministered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.

Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The most common adverse reactions reported with SINEMET have included dyskinesias, such as choreiform, dystonic, and other involuntary movements, and nausea. The following other adverse reactions have been reported with SINEMET: Body as a Whole Chest pain, asthenia. Cardiovascular Cardiac irregularities, hypotension, orthostatic effects including orthostatic hypotension, hypertension, syncope, phlebitis, palpitation.

Gastrointestinal Dark saliva, gastrointestinal bleeding, development of duodenal ulcer, anorexia, vomiting, diarrhea, constipation, dyspepsia, dry mouth, taste alterations. Hematologic Agranulocytosis, hemolytic and non-hemolytic anemia, thrombocytopenia, leukopenia. Hypersensitivity Angioedema, urticaria, pruritus, Henoch-Schönlein purpura, bullous lesions (including pemphigus-like reactions).

Musculoskeletal Back pain, shoulder pain, muscle cramps. Nervous System/Psychiatric Psychotic episodes including delusions, hallucinations, and paranoid ideation, bradykinetic episodes ("on-off" phenomenon), confusion, agitation, dizziness, somnolence, dream abnormalities including nightmares, insomnia, paresthesia, headache, depression with or without development of suicidal tendencies, dementia, pathological gambling, increased libido including hypersexuality, impulse control symptoms, seizures (including convulsions).

Respiratory Dyspnea, upper respiratory infection. Skin Rash, increased sweating, alopecia, dark sweat. Urogenital Urinary tract infection, urinary frequency, dark urine. Laboratory Tests Decreased hemoglobin and hematocrit; abnormalities in alkaline phosphatase, SGOT (AST), SGPT (ALT), LDH, bilirubin, BUN, Coombs test; elevated serum glucose; white blood cells, bacteria, and blood in the urine.

Other adverse reactions that have been reported with levodopa alone and with various carbidopa and levodopa formulations, and may occur with SINEMET are: Body as a Whole Abdominal pain and distress, fatigue. Cardiovascular Myocardial infarction. Gastrointestinal Gastrointestinal pain, dysphagia, sialorrhea, flatulence, bruxism, burning sensation of the tongue, heartburn, hiccups.

Metabolic Edema, weight gain, weight loss. Musculoskeletal Leg pain. Nervous System/Psychiatric Ataxia, extrapyramidal disorder, falling, anxiety, gait abnormalities, nervousness, decreased mental acuity, memory impairment, disorientation, euphoria, blepharospasm (which may be taken as an early sign of excess dosage; consideration of dosage reduction may be made at this time), trismus, increased tremor, numbness, muscle twitching, activation of latent Horner's syndrome, peripheral neuropathy.

Respiratory Pharyngeal pain, cough. Skin Malignant melanoma, flushing. Special Senses Oculogyric crises, diplopia, blurred vision, dilated pupils. Urogenital Urinary retention, urinary incontinence, priapism. Miscellaneous Bizarre breathing patterns, faintness, hoarseness, malaise, hot flashes, sense of stimulation. Laboratory Tests Decreased white blood cell count and serum potassium; increased serum creatinine and uric acid; protein and glucose in urine; decreased vitamin B 6 levels.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy No teratogenic effects were observed in a study in mice receiving up to 20 times the maximum recommended human dose of SINEMET. There was a decrease in the number of live pups delivered by rats receiving approximately two times the maximum recommended human dose of carbidopa and approximately five times the maximum recommended human dose of levodopa during organogenesis.

SINEMET caused both visceral and skeletal malformations in rabbits at all doses and ratios of carbidopa/levodopa tested, which ranged from 10 times/5 times the maximum recommended human dose of carbidopa/levodopa to 20 times/10 times the maximum recommended human dose of carbidopa/levodopa. There are no adequate or well-controlled studies in pregnant women.

It has been reported from individual cases that levodopa crosses the human placental barrier, enters the fetus, and is metabolized. Carbidopa concentrations in fetal tissue appeared to be minimal. Use of SINEMET in women of childbearing potential requires that the anticipated benefits of the drug be weighed against possible hazards to mother and child.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Levodopa has been detected in human milk. Caution should be exercised when SINEMET is administered to a nursing woman.

Mechanism of action

Mechanism of Action Parkinson's disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Its characteristic features include resting tremor, rigidity, and bradykinetic movements. Symptomatic treatments, such as levodopa therapies, may permit the patient better mobility.

Current evidence indicates that symptoms of Parkinson's disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson's disease apparently because it does not cross the blood-brain barrier. However, levodopa, the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain.

This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

Pharmacodynamics When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. For this reason, large doses of levodopa are required for adequate therapeutic effect, and these may often be accompanied by nausea and other adverse reactions, some of which are attributable to dopamine formed in extracerebral tissues.

Since levodopa competes with certain amino acids for transport across the gut wall, the absorption of levodopa may be impaired in some patients on a high protein diet. Carbidopa inhibits decarboxylation of peripheral levodopa. It does not cross the blood-brain barrier and does not affect the metabolism of levodopa within the central nervous system.

The incidence of levodopa-induced nausea and vomiting is less with SINEMET than with levodopa. In many patients, this reduction in nausea and vomiting will permit more rapid dosage titration. Since its decarboxylase inhibiting activity is limited to extracerebral tissues, administration of carbidopa with levodopa makes more levodopa available for transport to the brain.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Pharmacokinetics Carbidopa reduces the amount of levodopa required to produce a given response by about 75% and, when administered with levodopa, increases both plasma levels and the plasma half-life of levodopa, and decreases plasma and urinary dopamine and homovanillic acid.

The plasma half-life of levodopa is about 50 minutes, without carbidopa.

When carbidopa and levodopa are administered together, the half-life of levodopa is increased to about 1.5 hours.

In clinical pharmacologic studies, simultaneous administration of carbidopa and levodopa produced greater urinary excretion of levodopa in proportion to the excretion of dopamine than administration of the two drugs at separate times.

Pharmacokinetics (US label) US FDA label

Pharmacokinetics Carbidopa reduces the amount of levodopa required to produce a given response by about 75% and, when administered with levodopa, increases both plasma levels and the plasma half-life of levodopa, and decreases plasma and urinary dopamine and homovanillic acid. The plasma half-life of levodopa is about 50 minutes, without carbidopa.

When carbidopa and levodopa are administered together, the half-life of levodopa is increased to about 1.5 hours. At steady state, the bioavailability of carbidopa from SINEMET tablets is approximately 99% relative to the concomitant administration of carbidopa and levodopa. In clinical pharmacologic studies, simultaneous administration of carbidopa and levodopa produced greater urinary excretion of levodopa in proportion to the excretion of dopamine than administration of the two drugs at separate times.

Pyridoxine hydrochloride (vitamin B 6), in oral doses of 10 mg to 25 mg, may reverse the effects of levodopa by increasing the rate of aromatic amino acid decarboxylation. Carbidopa inhibits this action of pyridoxine; therefore, SINEMET can be given to patients receiving supplemental pyridoxine (vitamin B 6).

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Levodopa + Carbidopa 100 mg + 25 mg Tablet₱14.00–₱21.50Reference ₱14.55per tabletDPRI procurement range
Levodopa + Carbidopa 250 mg + 25 mg Tablet₱19.88–₱35.00Reference ₱21.45per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Levodopa + Carbidopa
PNF listingOral: 100 mg levodopa + 25 mg carbidopa per tablet
PNF listingOral: 250 mg levodopa + 25 mg carbidopa per tablet
PNF listingOral: 200 mg levodopa + 50 mg carbidopa extended release tablet
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. SINEMET · Organon LLC [US FDA-approved label, version 6, August 1, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b17b028-964a-473c-823d-81423535bd66
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .